Frequently Asked Questions
Protection and Advocacy Systems: Expanding Disabilities Network’s (P&As) Access to COVID 19 Vaccines (Version 1.0 dated 4-14-21)

The Administration for Community Living (ACL) announced a new funding opportunity of $4 million to support P&As increase vaccine access for people with disabilities. With funding and partnership support from the Centers for Disease Control and Prevention (CDC), ACL is providing grants to P&As to provide critical services to help communities combat COVID-19. A leading priority of this joint effort is to ensure vaccines are equally accessible to the disability population.

Allowable activities questions

Q1: What are the allowable activities for this award?
A1: All expenses related to the following activities are allowable to be charged to this award:
- Education about the importance of receiving a vaccine;
- Identifying people unable to independently travel to a vaccination site;
- Helping with scheduling a vaccine appointment;
- Arranging or providing accessible transportation;
- Providing companion/personal support;
- Reminding people of the second vaccination appointment if needed; and/or
- Providing technical assistance to local health departments or other entities on vaccine accessibility.

Q2: Can the funding be utilized to assist state vaccine information lines?
A2: In providing this funding, CDC intends to increase vaccinations among people with disabilities, their families, and support providers by utilizing ACL’s disability networks as a reliable source of information. If the state vaccine lines are providing specific support to people with disabilities, the expense would be appropriate.

Q3: Can the funding be used for combatting vaccine hesitancy?
A3: Yes, one of the purposes of the funding is for disseminating credible information about COVID-19 vaccines and helping direct those with questions to additional sources of information.

Q4: Can the funding be used to support vaccine equity efforts?
A4: Yes, the disability network is encouraged to use these funds to address inequity in COVID-19 vaccination access among people with disabilities, their family, support providers, and disability network staff and volunteers from communities defined by race, ethnicity, geography, disability, income, sexual orientation, gender identity, and other factors.

Q5: Can the funding be used to provide transportation stipends/vouchers to individuals?
Q5: Yes, arranging or providing accessible transportation to COVID-19 vaccination sites for people with disabilities and their caregivers is an allowable use of funds.

Q6: Can the funding be used to pay for staff to plan and organize the activities stated in Federal Register Notice, participate in meetings with local public health and other entities, and/or collect and analyze data on COVID-19 vaccination rates of people with disabilities, family caregivers, and disability network staff and volunteers?
A6: Yes, paying for staff for these activities is an allowable use of funds.

Q7: Can we use these funds to provide temporary staffing (personnel) to help with getting people appointments and help with transportation to get vaccination?
A7: Yes. These funds are designed to break down barriers to increase vaccine access.

Q8: Can the funding be used to serve anyone?
A8: This funding is intended to be used to serve people with disabilities, their families, support providers, and disability network staff and volunteers.

Grant and Fiscal policy questions

Q9: What is the Project Period for this award?
A9: Awards made under this announcement can have a start date of April 1, 2021 with an estimated end date of September 30, 2022. Funds must be obligated during this period. The period for liquidation of the obligations is through December 31, 2022.

Q10: Can we use multiple funding sources to fund these activities in the community?
A10: It is advisable that P&As monitor the use of these funds to ensure that they are allocated appropriately. However, ACL encourages collaboration.

Q11: Will funding received under this award be factored into funding formulas for other current or future awards my grantee currently receives from ACL?
A11: No. There will be no impact to future funding since these are one-time special funds from CDC for the purpose of increasing vaccine rates of people with disabilities, their families, and other support providers.

Q12: Does the P&A need to apply for these funds if they want to access the funding?
A12: Yes. In order to receive these funds a grantee must submit a signed letter of assurance. Please contact your Program Officer if you have not received these instructions.

Q13: Can a P&A decline this funding opportunity?
A13: Yes. To ensure proper tracking, we ask that you inform your Program Officer of not wanting to receive funds. We provided an optional template to sign and return to your program officer.
Q14: How are funding amounts determined and distributed?
A14: Based on the $4 million available for P&As, the formula distribution will be based on population of the state, with minimum allotments for states and territories with smaller populations. These projected amounts to be awarded to states or territories are listed in the Federal Register Notice posted on April 9, 2021. As some grantees may choose not to access this funding, more funding will be awarded to fewer states/territories, using the formula. We anticipate awarding the funds shortly after the 14-day deadline of April 23rd.

Q15: Can I transfer or other sub-award these funds to another entity?
A15: No. A grantee cannot transfer or sub-award these funds to another entity. However, a grantee may contract or otherwise purchase services or goods with these funds. It is ACL’s expectation that the recipient remain in control of the funds at all times.

Q16: Can the P&A purchase a vehicle to transport people with disabilities to vaccine appointments?
A16: The DD Act encourages transportation-related activities that result in people with disabilities having access to and use of transportation. Vehicle purchases are allowable per 2 CFR 200.48; however, prior approval is required. The approval process involves submitting a completed Large Purchase Request Form that can be provided by your grant or project officer to get started. In this form, the P&A will need to describe the vehicle’s proposed use after the project period ends. In addition, ACL requires that grant recipients include an analysis of lease and purchase alternatives to determine which would be the most economical and practical procurement of the recipient and the federal government. For assistance in determining whether to purchase a vehicle, please contact your project officer.

Q17: Will there be reporting requirements specific to this award?
A17: Yes. As indicated in the assurance template, recipients of this award must also submit programmatic and financial reports that reflect use of this funding. Specific procedural processes, reporting tools and deadlines are currently being developed by ACL and will be shared once finalized.

Q18: Will I need to track these funds separately?
A18: Yes. P&As will be expected to report specifically on the use of these funds and should begin to take steps to ensure funds are utilized in a way that allows for specific tracking and reporting.

Q19: Will this grant have its own SF-425 (FFR) and SF-425 supplemental forms?
A19: The grant requires semi-annual SF-425 financial reports.

Q20: Is this funding limited to services or goods purchased, or must it also be utilized for related administration or other costs?
A20: Costs charged to this award should follow the same rules, including those established in an approved Indirect Cost Rate, a Notice of Award or applicable under 45 CFR 75, as any other Federal funding source.
Q21: Since some sites will be in rural communities to provide vaccine access, can Disability Service Providers be included as part of this funding to get served and counted?
A21: Yes. Disability Service Providers are to be served and counted in all communities. Disability Service Providers provide critical support to keep the ID/DD population in their homes and in their communities. They may get reimbursed for travel costs.

Q22: Is this funding simply adding to our annual P&A allotment or is this a separate grant?
A22: These funds are considered a separate grant to support P&As with a specific focus to increase community access to vaccines. A separate grant number will be provided by ACL.

Q23: Are P&As permitted to obligate funding without a competitive bidding process?
A23: Given the extenuating circumstances and the urgency of services to increase vaccines access for people with disabilities, flexibility exists for grantees to consider expedited procurement methods.

Q24: One of the assurances is focused on collaborating with partners. Do you have guidance or best practice examples on how state recipients (DD Councils, P&As, UCEDD, CILs) can work together collectively to address needs in the community?
A24: We hope you can begin building off the existing relationships with DD Network Partners and CILs in your community in this effort. It just takes a phone call or an email. ACL encourages collaboration without duplicating efforts. As for accessing information on guidance and best practices, please consult with your TA provider to get promising concrete action steps that can be undertaken to strengthen partnerships. For additional resources, please visit ACL’s COVID-19 website and resource page titled How ACL’s Disability and Aging Network is Advancing Vaccination Efforts.